Care pathways, prescribing practices and treatment outcomes in major depressive disorder and treatment-resistant depression: retrospective, population-based cohort study

Care pathways, prescribing practices and treatment outcomes in major depressive disorder and treatment-resistant depression: retrospective, population-based cohort study

Background Despite the availability of effective therapies, many patients with major depressive disorder (MDD) develop treatment-resistant depression (TRD). Aims To evaluate and compare prescribing patterns, contact with specialist services and treatment outcomes in patients with MDD and TRD. Met...

Full description

Bibliographic Details
Main Authors:	Sofia Pappa, Moulesh Shah, Sophie Young, Tazneem Anwar, Timothy Ming
Format:	Article
Language:	English
Published:	Cambridge University Press 2024-01-01
Series:	BJPsych Open
Subjects:	Major depressive disorder treatment-resistant depression real-world data treatment pathway
Online Access:	https://www.cambridge.org/core/product/identifier/S2056472423006270/type/journal_article

Similar Items

Epidemiology of treatment resistant depression among major depressive disorder patients in Israel
by: Sarah Sharman Moser, et al.
Published: (2022-08-01)

Care pathways for people with major depressive disorder
by: R. Strawbridge, et al.
Published: (2022-06-01)

Efficacy of Botox versus Placebo for Treatment of Patients with Major Depression
by: Abbas ZAMANIAN, et al.
Published: (2017-06-01)

Real-world evidence from a retrospective study on suicide during depression: clinical characteristics, treatment patterns and disease burden
by: Han Wang, et al.
Published: (2024-04-01)

Treatment of Major Depressive Disorder in Pediatric Populations
by: Drew R. Neavin, et al.
Published: (2018-06-01)

Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study
by: Rebecca Strawbridge, et al.
Published: (2022-01-01)

Nitrous Oxide in Treatment Resistant Major Depression: Should We Laugh About It?
by: B. Leal, et al.
Published: (2022-06-01)

Real-world assessment of treatment inertia in the management of patients treated for major depressive disorder in the USA
by: John J Sheehan, et al.
Published: (2023-11-01)

Anhedonia and depression severity measures during ketamine administration in treatment-resistant depression
by: Aleksander Kwaśny, et al.
Published: (2024-02-01)

Predictors of Treatment Response and Length of Stay for Inpatients with Major Depression
by: I-Chih Cheng, et al.
Published: (2007-11-01)

Routine treatment pathways in a cohort of patients with major depression and suicidality in Italy: the ARIANNA observational study
by: Maurizio Pompili, et al.
Published: (2023-11-01)

Comparison of cognitive function in patients with treatment-resistant depression and drug-naive first-episode major depressive disorder
by: Zheng Chaodun, et al.
Published: (2021-10-01)

Neuroinflammatory Hypothesis in Major Depressive Disorder
by: Gulfizar Sozeri-Varma
Published: (2014-02-01)

Pharmacological Treatments for Patients with Treatment-Resistant Depression
by: Valerie L. Ruberto, et al.
Published: (2020-06-01)

Treatment-Resistant Depression in Poland—Epidemiology and Treatment
by: Piotr Gałecki, et al.
Published: (2022-01-01)

All-cause mortality in patients with treatment-resistant depression: a cohort study in the US population
by: Gang Li, et al.
Published: (2019-09-01)

The Impact of Residual Symptoms in Major Depression
by: Joshua A. Israel
Published: (2010-08-01)

A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment
by: Basurte-Villamor I, et al.
Published: (2022-05-01)

Concordance of the treatment patterns for major depressive disorders between the Canadian Network for Mood and Anxiety Treatments (CANMAT) algorithm and real-world practice in China
by: Lu Yang, et al.
Published: (2022-08-01)

Heart Rate Variability for the Prediction of Treatment Response in Major Depressive Disorder
by: Kwan Woo Choi, et al.
Published: (2020-06-01)

Suicide‐specific mortality among patients with treatment‐resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder alone
by: David M. Kern, et al.
Published: (2023-08-01)

Psychotherapy employed additionally to Psychopharmacotherapy is not related to Better Treatment Outcome in Major Depressive Disorder
by: L. Bartova, et al.
Published: (2022-06-01)

Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression
by: Bruijnzeel D, et al.
Published: (2016-05-01)

Osteocalcin levels decrease during the treatment of an acute depressive episode
by: Elis Bartečků, et al.
Published: (2022-08-01)

The dynamic interaction between symptoms and pharmacological treatment in patients with major depressive disorder: the role of network intervention analysis
by: Claudia Savia Guerrera, et al.
Published: (2023-11-01)

Program of algorithm for pharmacological treatment of major depressive disorder in China: Benefits or not?
by: Yuncheng Zhu, et al.
Published: (2023-11-01)

Experimental Therapeutics in Treatment-Resistant Major Depressive Disorder
by: Kaur M, et al.
Published: (2021-02-01)

The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review
by: Ludivine Boudieu, et al.
Published: (2023-12-01)

Prognostic Significance of Blood-Based Baseline Biomarkers in Treatment-Resistant Depression: A Literature Review of Available Studies on Treatment Response
by: Theano Gkesoglou, et al.
Published: (2022-07-01)

Routine treatment pathways of patients with major depression and active suicidal ideation with intent in Italy: interim results from the ARIANNA observational study
by: M. Pompili, et al.
Published: (2022-06-01)

A Southeast Asia Consensus on the Definition and Management of Treatment-Resistant Depression
by: Tor PC, et al.
Published: (2022-11-01)

Probiotics as a therapeutic strategy in Major Depressive Disorder
by: L. Vargas
Published: (2022-06-01)

Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment
by: Garcia-Toro Mauro, et al.
Published: (2012-09-01)

Biological correlates of treatment resistant depression: a review of peripheral biomarkers
by: Emiliana Mancuso, et al.
Published: (2023-10-01)

Functional connectivity analysis on electroencephalography signals reveals potential biomarkers for treatment response in major depression
by: Shiau-Shian Huang, et al.
Published: (2023-08-01)

Brain SPECT perfusion and PET metabolism as discordant biomarkers in major depressive disorder
by: Maud Tastevin, et al.
Published: (2020-10-01)

Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study
by: Antonio Del Casale, et al.
Published: (2022-02-01)

Effectiveness of trauma-focused treatment for adolescents with major depressive disorder
by: Corine Paauw, et al.
Published: (2019-12-01)

Safety and Tolerability of the Acute Ketamine Treatment in Treatment-Resistant Depression: Focus on Comorbidities Interplay with Dissociation and Psychomimetic Symptoms
by: Adam Włodarczyk, et al.
Published: (2023-01-01)

Biweekly vs Triweekly low dose intravenous ketamine acute series for severe major depression: A case report
by: Hernandorena Carolina, et al.
Published: (2023-12-01)